By Mitchell Young
New Haven: Achillion Pharmaceuticals [Nasdaq: ACHN] presented data on its three drug combination to treat Hepatitis C, at The International Liver Congress in Amsterdam in late April, just a week before the national kick-off of Hep C Awareness Month.
Jansen is financially responsible for all clinical trials and they initiated the Phase II clinical trial, last May of 300 participants of the drug combination, simeprevir, odalasvir and AL-335.
Jansen previously developed simeprevir and odalasvir, but required Achilion’s A-335 to achieve the effectiveness needed to cure Hep C.
The clinical results presented could be described as really good and really not so good....
Continue reading
Continue reading
No comments:
Post a Comment